Alios Biopharma | search
Click here to view Alios Biopharma news from 60+ newspapers.
Bookmark or Share- Johnson & Johnson Announces Completion Of Alios Biopharma ...The acquisition includes Alios BioPharma’s portfolio of potential therapeutics for viral infections with the promising compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus (RSV).
- Johnson & Johnson to acquire Alios BioPharma for $1.75bnUS-based Johnson & Johnson has signed an agreement to acquire a privately held clinical stage biopharmaceutical company, Alios BioPharma, for $1.75bn in cash.
- J&J to Acquire Alios BioPharma for $1.75 Billion - WSJJohnson & Johnson agreed to pay $1.75 billion to acquire privately held Alios BioPharma Inc., a developer of experimental treatments for viral diseases including hepatitis C. The deal would...
- J&J Goes Viral with $1.75B Alios BioPharma AcquisitionSeptember 30, 2014. Johnson & Johnson plans to acquire Alios BioPharma for $1.75 billion cash, in a deal that will expand the pharma giant’s viral-disease portfolio with two Phase II drugs and ...
- Johnson & Johnson Announces Agreement to Acquire Alios BioPharmaRead time: Less than a minute. Johnson & Johnson has announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash.
More
